

AMENDMENTS To The CLAIMS

Listing of Claims:

1-6. (Cancelled)

7. (Previously presented) A method for identifying a gamma secretase and/or a beta secretase modulator comprising the following steps:

a). identifying of a FADS2-interacting molecule by determining whether a given test compound is a FADS2-interacting molecule, and

b). determining whether the FADS2-interacting molecule of step a) is capable of modulating gamma secretase and/or beta secretase activity.

8. (Previously presented) The method of claim 7, wherein in step a) the test compound is brought into contact with FADS2 and the interaction of FADS2 with the test compound is determined.

9. (Previously presented) The method of claim 8, wherein the interaction of the test compound with FADS2 results in an inhibition of FADS2 activity.

10. (Previously presented) The method of claim 7, wherein in step b) the ability of the gamma secretase and/or the beta secrease to cleave APP is measured.

11. (Previously presented) A method for preparing a pharmaceutical composition for the treatment of neurodegenerative diseases comprising the following steps:

a). identifying a gamma secretase and/or beta secretase modulator according to claim 7, and

b). formulating the gamma secretase and/or beta secretase modulator to a pharmaceutical composition.

12-68. (Cancelled)